Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma

This study has been completed.
Novartis Pharmaceuticals
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center Identifier:
First received: December 1, 2010
Last updated: June 16, 2016
Last verified: June 2016
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: June 2016
  Primary Completion Date: June 2016 (Final data collection date for primary outcome measure)